FDA is extending the user fee date for Merck's zoster vaccine Zostavax by three months to May 25 in order to review additional information provided by the firm, Merck said Feb. 24
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
